Result: Mutations E92Q and T66K - which are also resistance-related mutations - were not present in frequencies high enough to be considered in the network.
Result: The residue 92, may show the mutation E92Q that was shown to reduce RAL susceptibility.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: P
Discussion: Additionally, any potential benefit of decreased viral fitness by M184V/I on the efficacy of dolutegravir/lamivudine may not outweigh the risk of virological failure with INSTI-R development, as it is possible for M184V and INSTI-R to co-develop while failing a dolutegravir/lamivudine regimen.In vitro studies further suggest that viral fitness defects can be overcome by drug resistance in the presence of antiretroviral drugs: HIV-1 with M184V and INSTI-R (E92Q, Q148R or N155H) grows more efficiently than WT HIV-1 in the presence of emtricitabine and the INSTI elvitegravir at physiological concentrations.
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
PMID: 31169022
2019
AIDS research and human retroviruses
Abstract: Prevalence of elvitegravir-associated DRMs T66A/I/K, E92Q, S147G, and the dolutegravir-associated DRM R263K increased.
Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
Discussion: Although the in vitro replication capacity mutants containing E92Q or G118R was markedly reduced, their transmission fitness is not known as it is also unknown if their transmission potential may be increased if viremias are high as it is the case of acute HIV infection.
Discussion: It will be important to see if the G118R, G140R and E92Q/G mutations selected in SIV in vivo will also be selected in patients failing CAB-containing regimens, and if these mutations will confer similar levels of drug resistance in HIV.
Discussion: Overall, these results demonstrate intermediate to high-level resistance to CAB and other PMID: 31037930
2019
Revista espanola de quimioterapia
Table: E92Q
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.
PMID: 30229661
2019
AIDS research and human retroviruses
Abstract: In the former group, both major INSTI resistance cases involved the nonpolymorphic E92Q mutation in the integrase strand.
Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.
Abstract: Some mutations, such as G118R, previously shown to severely impair the replication capacity in vitro, were associated with more sustained virological and immunological benefits of continued DTG therapy, while other mutations, such as E92Q and G140A/Q148K, were associated with more variable outcomes.
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.
PMID: 29617822
2018
The Journal of infectious diseases
Abstract: INSTI-RAMs (S230R, R263K, N155H, and E92Q+N155H) were detected in 4 patients, no INSTI-RAMs were detected in 4 patients, and sequencing of the integrase gene was unsuccessful in 2 patients.
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Introduction: In the study of Anstett et al., L74M, E92Q, T97A, E157Q and G163R resistance mutations were introduced into NL4.3 subtype B HIV-1 vectors harboring N155H and R263K in tandem.
Introduction: They found that the addition of T97A, E157Q or G163R mutation somewhat improved the affinity of the double-mutant N155H-R263K for its target DNA substrate, while the presence of L74M or E92Q had a negative effect on this step.
Introduction: They showed that the presence of the
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Introduction: The resistance patterns observed in HIV-1 patients on a raltegravir containing regimen are very diverse and Q148H/K/R (usually with G140A/C/S and/or E138A/K) and N155H (often together with E92Q or V151I) mutations are observed more frequently than Y143 mutations.
Result: The N155H-virus additionally acquired mutations V151I and later E92Q.
HIV mutation literature information.
PMID: 
2019
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT